Technology Bundle ID: TAB-2650

Method of Enhancing Opsonophagocytosis

Request More Info
Licensing Contact:
Edwin Ades (CDC), George Carlone (CDC), GowriSankar Rajam (CDC), Jacquelyn Sampson (CDC), Joseph Caba (CDC), Joseph Martinez (CDC), Nikkol Atwell-Melnick Melnick (CDC), Sandra Steiner (CDC)
Therapeutic Area: 
Infectious Disease
Development Status: 
  • Pre-clinical
  • In vitro data available
  • In vivo data available (animal)
Institute or Center: 

This invention aims to bolster the human body's own mechanisms to fight infection by enhancing an innate immune response, opsonophagocytosis. The specific 24 amino acid sequence (P4) acts as a polymorphonuclear cell activator. P4 can be administered in vivo along with a disease's specific antibody to enhance systemic bacterial clearance, thus leading to prolonged survival. This technology enhances the body's response to infections such as S. pneumoniae and S. aureus.

  • Opsonic therapy
  • Passive immunization
  • Enhancement of pathogen clearing
  • Synergistic use with other therapies
  • Multiple in vivo studies indicate significant improvements in recipient outcomes
  • Highly adaptable and can be combined with a number of alternate therapies
  • Enhances opsonophagoctyosis to achieve therapeutically effective results


PCT Application PCT/US2005/027290
Filed on 2005-07-29
PCT Application PCT/US2009/052384
Filed on 2009-07-31
US Application 60/682,495
Filed on 2005-05-19
US Application 61/085,208
Filed on 2008-07-31
US Pat 7,919,104

Issued 2011-04-05
US Pat 8,431,134

Issued 2013-04-30
US Pat 9,101,582

Issued 2015-08-11

Various foreign counterparts such as in Australia, Europe, Hong Kong, and Canada.


Bangert M, et al.
PMID 22457294
Melnick N, et al.
PMID 19386795
Weeks JN, et al.
PMID 21383090


Sep 19, 2013

Data Source: